



Attorney Docket No. 0275/56972

Inventor Oon et al.

Total Pages 2

Express Mail Label No. EL018280915US

#17  
Reg. CPA  
Filing  
7/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

ASSISTANT COMMISSIONER FOR PATENTS  
Box CPA  
Washington, D. C. 20231

July 22, 2002

JUL 29 2002

TECH CENTER 1600/2900

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Sir:

This is a request for filing a X CONTINUATION    DIVISIONAL application under 37 CFR 1.53(d) continued prosecution application (CPA) of pending prior application Serial No. 09/362,394, filed on July 28, 1999 entitled DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP

CFR sent  
7/31/02

1.    Enter the unentered amendment previously filed on    under 37 CFR 1.116 in the prior nonprovisional application.

2. X A preliminary amendment is enclosed.

3.    This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).

a.    DELETE the following inventor(s) named in the prior nonprovisional application:   

b.    The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

4.    A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.

5.    Information Disclosure Statement (IDS) is enclosed:

a.    PTO-1449

b.    Copies of IDS Citations

6.    Small entity status:

a.    A small entity statement is enclosed.

b.    A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.

c.    Is no longer claimed.

07/25/2002 MGBREM1 00000002 09362394

01 FC:131  
02 FC:102  
03 FC:103

740.00 OP  
504.00 OP  
522.00 OP ✓

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELED BY AMENDMENT

					Rate			Fee	
	Number Filed		Number Extra*		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	49 -20	=	29	x	\$ 9	\$ 18	=	\$0	\$522
Indep. Claims	9 - 3	=	6	x	\$ 42	\$ 84	=	\$ 0	\$504
Multiple Dependent Claims Presented: Yes___ No <u>X</u>					\$135	\$270	=	\$ 0	\$0
If the difference in column 1 is less than zero, enter "0" in column 2					Basic Fee			\$ 0	\$740
					Total Fee			\$ 0	\$1766

7. X A check in the amount of \$1766.00 to cover the filing fee.
8. X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any overpayment to Deposit Account No. 03-3125.
- X Filing fees under 37 C.F.R. § 1.16.
- X Patent application processing fees under 37 C.F.R. §1.17.
- \_\_\_ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
9. X Three copies of this sheet are enclosed.
10. X Other (identify) Express Mail Certificate of Mailing bearing label No. EL018280915US  
dated July 18, 2002

July 22, 2002  
Date

Respectfully submitted,

  
John P. White, Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, NY 10036  
Tel.: (212) 278-0400



RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

Dkt. 56972/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chong-Jin Oon, Wei-Ning Chen, Ai-Lin Leong and  
Shiuan Koh

Serial No.: CPA of 09/362,394

Filed : July 28, 1999

For : DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE  
ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND  
ITS APPLICATION ON GENE CHIP

1185 Avenue of the Americas  
New York, New York 10036  
July 22, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX CPA

Sir:

PRELIMINARY AMENDMENT

This Preliminary Amendment is submitted in connection with the  
above-identified application.

Please amend the subject application as follows:

In the Specification

Please replace the paragraph starting at page 9, line 14 with the  
following rewritten paragraph:

21

--One of the applications of the present invention is the  
detection of the human hepatitis B virus surface antigen  
mutant. 145 (Glycine to Arginine) using a solid glass  
supports device. In the present invention, further  
modifications have been added to two oligonucleotides  
(listed herein): 5'-TACGGACGGAACT-3' (SEQ ID NO:3), and